355 related articles for article (PubMed ID: 9803007)
1. p53 tumour suppressor gene mutations in benign prostatic hyperplasia and prostate cancer.
Schlechte H; Lenk SV; Löning T; Schnorr D; Rudolph BD; Ditscherlein G; Loening SA
Eur Urol; 1998; 34(5):433-40. PubMed ID: 9803007
[TBL] [Abstract][Full Text] [Related]
2. TP53 mutation in prostate needle biopsies--comparison with patients follow-up.
Ecke TH; Schlechte HH; Hübsch A; Lenk SV; Schiemenz K; Rudolph BD; Miller K
Anticancer Res; 2007; 27(6B):4143-8. PubMed ID: 18225585
[TBL] [Abstract][Full Text] [Related]
3. Mutation of the tumor suppressor gene p53 in human prostate and bladder cancers--investigation by temperature gradient gel electrophoresis (TGGE).
Schlechte HH; Schnorr D; Löning T; Rudolph BD; Pohrt UM; Loening SA
J Urol; 1997 Mar; 157(3):1049-53. PubMed ID: 9072541
[TBL] [Abstract][Full Text] [Related]
4. Prostate stem cell antigen mRNA expression in preoperatively negative biopsy specimens predicts subsequent cancer after transurethral resection of the prostate for benign prostatic hyperplasia.
Zhao Z; Liu J; Li S; Shen W
Prostate; 2009 Sep; 69(12):1292-302. PubMed ID: 19462463
[TBL] [Abstract][Full Text] [Related]
5. The clinicopathologic patterns of prostatic diseases and prostate cancer in Saudi patients.
Mosli HA; Abdel-Meguid TA; Al-Maghrabi JA; Kamal WK; Saadah HA; Farsi HM
Saudi Med J; 2009 Nov; 30(11):1439-43. PubMed ID: 19882057
[TBL] [Abstract][Full Text] [Related]
6. Expression analysis of thrombospondin 2 in prostate cancer and benign prostatic hyperplasia.
Matos AR; Coutinho-Camillo CM; Thuler LC; Fonseca FP; Soares FA; Silva EA; Gimba ER
Exp Mol Pathol; 2013 Jun; 94(3):438-44. PubMed ID: 23470460
[TBL] [Abstract][Full Text] [Related]
7. Correlation of genetic and immunodetection of TP53 mutations in malignant and benign prostate tissues.
Wertz IE; Deitch AD; Gumerlock PH; Gandour-Edwards R; Chi SG; de Vere White RW
Hum Pathol; 1996 Jun; 27(6):573-80. PubMed ID: 8666367
[TBL] [Abstract][Full Text] [Related]
8. PSCA mRNA expression in preoperatively negative prostate biopsies predicts incidental prostate cancer in patients undergoing transurethral resection of the prostate for benign prostatic hyperplasia.
Zhao Z; Ma W; Zeng G; Qi D
J Surg Oncol; 2011 Nov; 104(6):672-8. PubMed ID: 21674503
[TBL] [Abstract][Full Text] [Related]
9. TP53 gene mutations in prostate cancer progression.
Ecke TH; Schlechte HH; Schiemenz K; Sachs MD; Lenk SV; Rudolph BD; Loening SA
Anticancer Res; 2010 May; 30(5):1579-86. PubMed ID: 20592345
[TBL] [Abstract][Full Text] [Related]
10. Infrequent involvement of p53 gene mutations in the tumourigenesis of Japanese prostate cancer.
Uchida T; Wada C; Shitara T; Egawa S; Koshiba K
Br J Cancer; 1993 Oct; 68(4):751-5. PubMed ID: 7691145
[TBL] [Abstract][Full Text] [Related]
11. Interferon-gamma and its functional receptors overexpression in benign prostatic hyperplasia and prostatic carcinoma: parallelism with c-myc and p53 expression.
Royuela M; de Miguel MP; Ruiz A; Fraile B; Arenas MI; Romo E; Paniagua R
Eur Cytokine Netw; 2000 Mar; 11(1):119-27. PubMed ID: 10705309
[TBL] [Abstract][Full Text] [Related]
12. Retinoic acid receptor β2 (RARβ2): nonivasive biomarker for distinguishing malignant versus benign prostate lesions from bodily fluids.
Dumache R; Puiu M; Minciu R; Bardan R; David D; Tudor A; Bumbăcilă B
Chirurgia (Bucur); 2012; 107(6):780-4. PubMed ID: 23294958
[TBL] [Abstract][Full Text] [Related]
13. Abnormal p53 expression is rare in clinically localized human prostate cancer: comparison between immunohistochemical and molecular detection of p53 mutations.
Mottaz AE; Markwalder R; Fey MF; Klima I; Merz VW; Thalmann GN; Ball RK; Studer UE
Prostate; 1997 Jun; 31(4):209-15. PubMed ID: 9180930
[TBL] [Abstract][Full Text] [Related]
14. Lack of evidence of HPV etiology of prostate cancer following radical surgery and higher frequency of the Arg/Pro genotype in Turkish men with prostate cancer.
Aydin M; Bozkurt A; Cikman A; Gulhan B; Karabakan M; Gokce A; Alper M; Kara M
Int Braz J Urol; 2017; 43(1):36-46. PubMed ID: 28124524
[TBL] [Abstract][Full Text] [Related]
15. Prohibitin identified by proteomic analysis of prostate biopsies distinguishes hyperplasia and cancer.
Ummanni R; Junker H; Zimmermann U; Venz S; Teller S; Giebel J; Scharf C; Woenckhaus C; Dombrowski F; Walther R
Cancer Lett; 2008 Aug; 266(2):171-85. PubMed ID: 18384941
[TBL] [Abstract][Full Text] [Related]
16. Clinical significance of high-grade prostatic intraepithelial neoplasia in transurethral resection specimens.
Pacelli A; Bostwick DG
Urology; 1997 Sep; 50(3):355-9. PubMed ID: 9301697
[TBL] [Abstract][Full Text] [Related]
17. P53 tumour-suppressor gene mutations are mainly localised on exon 7 in human primary and metastatic prostate cancer.
Dahiya R; Deng G; Chen KM; Chui RM; Haughney PC; Narayan P
Br J Cancer; 1996 Jul; 74(2):264-8. PubMed ID: 8688333
[TBL] [Abstract][Full Text] [Related]
18. Frequent 14-3-3 sigma promoter methylation in benign and malignant prostate lesions.
Henrique R; Jerónimo C; Hoque MO; Carvalho AL; Oliveira J; Teixeira MR; Lopes C; Sidransky D
DNA Cell Biol; 2005 Apr; 24(4):264-9. PubMed ID: 15812243
[TBL] [Abstract][Full Text] [Related]
19. Effect of mtDNA mutation on tumor malignant degree in patients with prostate cancer.
Yu JJ; Yan T
Aging Male; 2010 Sep; 13(3):159-65. PubMed ID: 20136572
[TBL] [Abstract][Full Text] [Related]
20. Calculated fast-growing benign prostatic hyperplasia--a risk factor for developing clinical prostate cancer.
Hammarsten J; Högstedt B
Scand J Urol Nephrol; 2002; 36(5):330-8. PubMed ID: 12487736
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
